CryoLife establishes sales force in Germany:
This article was originally published in Clinica
Executive Summary
Biomaterial and biosurgical device specialist CryoLife (Kennesaw, Georgia) has set up a direct sales force in Freiburg, Germany, through its European subsidiary, CryoLife Europa. The team will focus on sales of CryoLife's BioGlue, a surgical adhesive product, and the distribution of its allograft tissues. It is the company's second direct sales force outside the US after its UK-based team, and will operate in the Southern and Northeast regions of Germany, including Berlin, Hamburg and Leipzig. The company is looking to spread operations to Western Germany by the end of 2007.
You may also be interested in...
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.